Anti-diabetic, Anti-cancer Potential and Anti HIV of Bitter Gourd (Momordica charantia) Extract: A Mini Review

Abstract

Aims: To review the antidiabetic properties, pharmacological characteristics, and phytochemical research on Momordica Ccharantia (bitter gourd) and assess its potential as a therapeutic agent for diabetes and cancer prevention. Study Design: Review of existing literature and research studies, including pre-clinical trials and animal and in vitro studies. Methodology: Analysis of traditional uses, pharmacological data, and phytochemical research on M. Charantia. Evaluation of anti-diabetic and anti-HIV properties based on available studies. Results: • Charantia has shown anti-diabetic and hypoglycemic effects in pre-clinical studies. • Limited and unreliable clinical data due to poor research design and inadequate statistical power. • Recent studies indicate potential anti-tumor, anti-diabetic, and anti-HIV properties. • Plant extract components have demonstrated effectiveness in cancer prevention through immune function enhancement, induction of cell death, and inhibition of cancer-related processes. Conclusion: M. Charantia holds promise as a therapeutic agent for diabetes management and cancer prevention. However, there is a need for better-designed clinical trials to confirm its efficacy and establish reliable clinical evidence.